title: A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
abstract: BACKGROUND
  Constitutive activation of nuclear factor κB (NF-κB) is a hallmark of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL). Mutations in the A20 gene activate NF-κB, but the prognostic value of A20 mutations in ABC-DLBLC is unclear.
  
  
  OBJECTIVE
  To investigate the prognostic value of A20 mutation in ABC-DLBCL patients.
  
  
  METHODS
  The somatic mutation of A20 was investigated in 68 de novo ABC-DLBCLs by PCR/sequencing. The Kaplan-Meier method was used to estimate median overall survival (OS) and progression-free survival (PFS).
  
  
  RESULTS
  The A20 mutation rate in ABC-DLBCL patients was 29.4%. Complete remission rates were 35% and 45.8% in patients with and without A20 mutations, respectively (P = 0.410). In patients with and without A20 mutations, the median OS was 24.0 and 30.6 months, respectively (P = 0.58), and the median PFS was 15 and 17.4 months, respectively (P = 0.52). None of the differences between the patient groups were significant.
  
  
  CONCLUSIONS
  Our findings suggested that the A20 mutation is a frequent event in ABC-DLBCLs. However, there was no significant difference in PFS and OS in patients with or without A20 mutations. Further study is required to completely exclude A20 somatic mutation as a prognostic marker in the ABC subtype of DLBLC.
authors.affiliation: Department of Chemotherapy, Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
authors.forename: Hong
authors.initials: H
authors.lastname: Cen
authors.affiliation: Department of Chemotherapy, Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Tan
authors.affiliation: Department of Chemotherapy, Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
authors.forename: Baoping
authors.initials: B
authors.lastname: Guo
mesh_terms: D001402:B-Lymphocytes / Q000473:pathology*; D002470:Cell Survival / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D008213:Lymphocyte Activation / Q000235:genetics; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D016328:NF-kappa B / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics*; D011379:Prognosis; D015398:Signal Transduction / Q000235:genetics; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3
chemical_list: D004268:DNA-Binding Proteins; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B; D009687:Nuclear Proteins; C076529:TNFAIP3 protein, human; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3